

Patient Name : MRS. SARANYA A P

Age / Gender: 35 years / Female

Patient ID: 89224

Referral : MediWheel

**Collection Time :** Mar 25, 2022, 09:09 a.m. **Reporting Time :** Mar 25, 2022, 03:38 p.m.

Sample ID:

Test Description	Value(s)	Reference Range	
COMPLETE BLOOD COUNT ( CBC )			
Hemoglobin (Hb)	13.4	12.0 - 15.0	gm/dL
Erythrocyte (RBC) Count	4.73	3.8 - 4.8	mil/cu.mm
Packed Cell Volume (PCV)	37.9	36 - 46	%
Mean Cell Volume (MCV)	80.13	83 - 101	fL
Mean Cell Haemoglobin (MCH)	28.33	27 - 32	pg
Mean Corpuscular Hb Concn. (MCHC)	35.36	31.5 - 34.5	g/dL
Red Cell Distribution Width (RDW)	12.9	11.6 - 14.0	%
Total Leucocytes (WBC) Count	7400	4000-10000	cell/cu.mm
Neutrophils	58	40 - 80	%
Lymphocytes	30	20 - 40	%
Monocytes	6	2 - 10	%
Eosinophils	6	1 - 6	%
Basophils	0	1-2	%
Absolute Neutrophil Count	4292	2000 - 7000	/c.mm
Absolute Lymphocyte Count	2220	1000 - 3000	/c.mm
Absolute Monocyte Count	444	200 - 1000	/c.mm
Absolute Eosinophil Count	444	20 - 500	/c.mm
Absolute Basophils Count	0	20 - 100	/c.mm
Platelet Count	426	150 - 410	10^3/ul
Mean Platelet Volume (MPV)	9.4	7.2 - 11.7	fL
PCT	0.40	0.2 - 0.5	%
PDW	9.6	9.0 - 17.0	%
ESR	75.0	12.0 - 15.0	mm/hr

\*\*END OF REPORT\*\*

DR.UMA SAROJINI .K MBBS.,DCP.,





Patient Name: MRS. SARANYA A P

Age / Gender: 35 years / Female

Patient ID: 89224

Referral: MediWheel

**Collection Time :** Mar 25, 2022, 09:09 a.m. **Reporting Time :** Mar 25, 2022, 03:38 p.m.

Sample ID:

Test Description Value(s) Reference Range

# **URINE COMPLETE ANALYSIS,**

#### **Physical Examination**

Quantity 30 - ml

Colour Pale Yellow Pale yellow/Yellow

Appearance Cloudy Clear

 Specific Gravity
 1.030
 1.005-1.025

 pH
 5.0
 5.0 - 8.0

 Deposit
 Present
 Absent

### **Chemical Examination**

**Protein Trace** Absent Sugar Absent Absent **Ketones** Absent Absent **Bile Salt** Absent Absent **Bile Pigment** Absent Absent Normal Urobilinogen Normal

## Microscopic Examination (/hpf)

**Pus Cell** Upto 5 4-5 1-2 **Epithelial Cells** Upto 5 **Red Blood Cells** Absent Absent Casts Absent Absent Crystals Absent Absent **Amorphous Deposit** Absent Absent **Yeast Cells** Absent Absent **Bacteria** Absent Absent Other findings Not seen Not seen



Scan to Validate



Page 2 of 12



Patient Name: MRS. SARANYA A P

Age / Gender: 35 years / Female

Patient ID: 89224

Referral : MediWheel

**Collection Time :** Mar 25, 2022, 09:09 a.m. **Reporting Time :** Mar 25, 2022, 03:38 p.m.

Sample ID:

Test Description

Value(s)

Reference Range

\*\*END OF REPORT\*\*

DR.UMA SAROJINI .K MBBS.,DCP.,





Patient Name: MRS. SARANYA A P

Age / Gender: 35 years / Female

Patient ID: 89224

Referral: MediWheel

**Collection Time :** Mar 25, 2022, 09:09 a.m. **Reporting Time :** Mar 25, 2022, 03:38 p.m.

Sample ID:

Test Description Value(s) Reference Range

# **BLOOD GROUP & RH TYPING**

Blood Group (ABO typing)

Method : Manual-Hemagglutination RhD Factor (Rh Typing)

Method : Manual hemagglutination

"B"

**Positive** 

\*\*END OF REPORT\*\*

DR.UMA SAROJINI .K MBBS.,DCP.,





Patient Name: MRS. SARANYA A P

Age / Gender: 35 years / Female

**Patient ID**: 89224

Referral: MediWheel

**Collection Time :** Mar 25, 2022, 09:09 a.m. **Reporting Time :** Mar 25, 2022, 03:38 p.m.

Sample ID:

			001000422
Test Description	Value(s)	Reference Range	
Glycosylated HbA1c			
HbA1c (GLYCOSYLATED HEMOGLOBIN),	5.5		%
BLOOD			
Method : (HPLC, NGSP certified)			
Estimated Average Glucose :	111.15	-	mg/dL
Interpretation			
As per American Diabetes Association (ADA)			
Reference Group	HbA1c in %		
Non diabetic adults >=18 years	<5.7		
At risk (Prediabetes)	5.7 - 6.4		
Diagnosing Diabetes	>= 6.5		
	Age > 19 year	S	
	Goal of therap	y: < 7.0	
Therapeutic goals for glycemic control	Action sugges	ted: > 8.0	
	Age < 19 year	s	
	Goal of therap	y: <7.5	

## Note:

- Since HbA1c reflects long term fluctuations in the blood glucose concentration, a diabetic patient who is recently under good control may still have a high concentration of HbA1c. Converse is true for a diabetic previously under good control but now poorly controlled.
- 2. Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long life expectancy and no significant cardiovascular disease. In patients with significant complications of diabetes, limited life expectancy or extensive co-morbid conditions, targeting a goal of < 7.0 % may not be appropriate.

#### Comments

HbA1c provides an index of average blood glucose levels over the past 8 - 12 weeks and is a much better indicator of long term glycemic control as compared to blood and urinary glucose determinations.

 $\bigcup \bigcup \bigvee \bigvee \bigvee$ 

DR.UMA SAROJINI .K MBBS.,DCP.

## Scan to Validate



Page 5 of 12



Patient Name: MRS. SARANYA A P

Age / Gender: 35 years / Female

Patient ID: 89224

Referral: MediWheel

**Collection Time :** Mar 25, 2022, 09:09 a.m. **Reporting Time :** Mar 25, 2022, 03:38 p.m.

Sample ID:

**Test Description** 

Value(s)

Reference Range

## ADA criteria for correlation between HbA1c & Mean plasma glucose levels.

HbA1c(%)	Mean Plasma Glucose (mg/dL)
6	126
7	154
8	183
9	212
10	240
11	269
12	298

\*\*END OF REPORT\*\*







Patient Name: MRS. SARANYA A P

Age / Gender: 35 years / Female

Patient ID: 89224

Referral: MediWheel

**Collection Time :** Mar 25, 2022, 09:09 a.m. **Reporting Time :** Mar 25, 2022, 03:38 p.m.

Sample ID:

Test Description	Value(s)	Reference Range	
<b>THYROID PROFILE TEST - TOTAL</b>			
T3-Total	147.0	60 - 200	ng/dL
T4-Total	15.3	4.52 - 12	ug/dL
TSH-Ultrasensitive	6.00	0.32 - 5.5	uIU/mL
Method : CLIA		First Trimester : 0.1-2.5	
		Second Trimester: 0.2-3.0	
		Third trimester: 0.3-3.0	

#### Interpretation

TSH	Т3	T4	Suggested Interpretation for the Thyroid Function Tests Pattern
Raised	Within range	Within range	Raised Within Range Within Range .Isolated High TSHespecially in the range of 4.7 to 15 m1U/m1 is commonly associated with Physiological & Biological TSH Variability. Subclinical Autoimmune Hypothyroidism.Intermittent 14 therapy for hypothyroidism .Recovery phase after Non-Thyroidal illness"
Raised	Decreased	Decreased	Chronic Autoimmune Thyroiditis Post thyroidectomy,Post radioiodine Hypothyroid phase of transient thyroiditis"
Raised or within range	Raised	Raised or within range	Interfering antibodies to thyroid hormones (anti-TPO antibodies)Intermittent 14 therapy or T4 overdose •Drug interference- Amiodarone, Heparin,Beta blockers,steroids, anti-epileptics.
Decreased	Raised or within range	Raised or within range	Isolated Low TSH -especially in the range of 0.1 to 0.4 often seen in elderly & Range Range associated with Non-Thyroidal illness .Subclinical Hyperthyroidism .Thyroxine ingestion'
Decreased	Decreased	Decreased	Central Hypothyroidism .Non-Thyroidal illness .Recent treatment for Hyperthyroidism (TSH remains suppressed)"
Decreased	Raised	Raised	Primary Hyperthyroidism (Graves' disease). Multinodular goitre, Toxic nodule •Transient thyroiditis: Postpartum, Silent (lymphocytic), Postviral (granulomatous, subacute, DeQuervain's), Gestational thyrotoxicosis with hyperemesis gravidarum"
Decreased Within Rang	Raised	Within range	T3 toxicosis •Non-Thyroidal illness
Within range	Decreased	Within range	Isolated Low T3-often seen in elderly & associated Non-Thyroidal illness In elderly the drop in 13 level can be upto 25%.

\*\*END OF REPORT\*\*

DR.UMA SAROJINI .K MBBS.,DCP.,





Patient Name: MRS. SARANYA A P

Age / Gender: 35 years / Female

Patient ID: 89224

Referral: MediWheel

**Collection Time :** Mar 25, 2022, 09:09 a.m. **Reporting Time :** Mar 25, 2022, 03:38 p.m.

Sample ID:

Test Description	Value(s)	Reference Range	
LIPID PROFILE			
Cholesterol-Total  Method : Spectrophotometry	215.0	Desirable level   < 200 Borderline High   200-239 High   >or = 240	mg/dL
Triglycerides  Method : Serum, Enzymatic, endpoint	137.0	Normal: < 150 Borderline High: 150-199 High: 200-499 Very High: >= 500	mg/dL
HDL Cholesterol  Method : Serum, Direct measure-PEG	43.0	Normal: > 40 Major Risk for Heart: < 40	mg/dL
LDL Cholesterol  Method : Enzymatic selective protection	144.60	Optimal < 100 Near / Above Optimal 100-129 Borderline High 130-159 High 160-189 Very High >or = 190	mg/dL
VLDL Cholesterol  Method : Serum, Enzymatic	27.40	6 - 38	mg/dL
CHOL/HDL Ratio  Method : Serum, Enzymatic	5.0	3.5 - 5.0	
LDL/HDL Ratio  Method : Serum, Enzymatic  Note:	3.36	2.5 - 3.5	
8-10 hours fasting sample is required.			

\*\*END OF REPORT\*\*

A SAROJINI .K MBBS.,DCP.,





Patient Name: MRS. SARANYA A P

Age / Gender: 35 years / Female

Patient ID: 89224

Referral: MediWheel

**Collection Time :** Mar 25, 2022, 09:09 a.m. **Reporting Time :** Mar 25, 2022, 03:38 p.m.

Sample ID:

			001000422
Test Description	Value(s)	Reference Range	
RENAL PROFILE			
Urea	17.0	15-36	mg/dL
Method : Uricase			
Blood Urea Nitrogen-BUN	7.93	7 - 17	mg/dL
Method : Serum, Urease			
Creatinine	0.65	0.52-1.25	mg/dL
Method : Serum, Jaffe			
Uric Acid	5.1	2.5 - 6.2	mg/dL
Method : Serum, Uricase			
Remark:			
In blood, Urea is usually reported as BUN an	d expressed in mg/dl.	BUN mass units can be converte	ed to urea mass units by

In blood, Urea is usually reported as BUN and expressed in mg/dl. BUN mass units can be converted to urea mass units by multiplying by 2.14.

\*\*END OF REPORT\*\*

DR.UMA SAROJINI .K MBBS.,DCP.,





Patient Name: MRS. SARANYA A P

Age / Gender: 35 years / Female

Patient ID: 89224

Referral: MediWheel

**Collection Time :** Mar 25, 2022, 09:09 a.m. **Reporting Time :** Mar 25, 2022, 03:38 p.m.

Sample ID:

Test Description	Value(s)	Reference Range	
LIVER FUNCTION TEST			
Total Protein	7.4	6.3-8.2	g/dL
Method : Serum, Biuret, reagent blank end point			<b>3</b> ·
Albumin	3.6	3.5-5.0	g/dL
Method : Serum, Bromocresol green			•
Globulin	3.80	1.8 - 3.6	g/dL
Method : Serum, EIA			
A/G Ratio	0.95	1.2 - 2.2	
Method : Serum, EIA			
Bilirubin - Total	0.9	0.3-1.2	mg/dL
Method : Serum, Jendrassik Grof			
Bilirubin - Direct	0.2	< 0.2	mg/dL
Method : Serum, Diazotization			
Bilirubin - Indirect	0.7	0.1 - 1.0	mg/dL
Method : Serum, Calculated			
SGOT	30.0	14-36	U/L
Method : Serum, UV with P5P, IFCC 37 degree			
SGPT	20.0	9-52	U/L
Method : Serum, UV with P5P, IFCC 37 degree			
Alkaline Phosphatase	61.0	30 - 120	U/L
Method : PNPP-AMP Buffer/Kinetic			
GGT-Gamma Glutamyl Transpeptidae  Method : Serum, G-glutamyl-carboxy-nitoanilide	37.0	< 38	U/L

\*\*END OF REPORT\*\*







Patient Name: MRS. SARANYA A P

Age / Gender: 35 years / Female

Patient ID: 89224

Referral : MediWheel

**Collection Time :** Mar 25, 2022, 09:09 a.m. **Reporting Time :** Mar 25, 2022, 03:38 p.m.

Sample ID:

Test Description	Value(s)	Reference Range	
GLUCOSE (F)			
Glucose fasting  Method: GOD-POD	106.0	Normal: 70 - 120	mg/dL

\*\*END OF REPORT\*\*

DR.UMA SAROJINI .K MBBS.,DCP.,





Patient Name: MRS. SARANYA A P

Age / Gender: 35 years / Female

Patient ID: 89224

Referral: MediWheel

**Collection Time :** Mar 25, 2022, 09:09 a.m. **Reporting Time :** Mar 25, 2022, 03:38 p.m.

Sample ID:

Test Description	Value(s)	Reference Range	
GLUCOSE (PP)  Blood Glucose-Post Prandial  Method : GOD-POD	170.0	80- 140	mg/dL

\*\*END OF REPORT\*\*

DR.UMA SAROJINI .K MBBS.,DCP.,

